title: A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
abstract: In an earlier study of previously untreated patients with chronic lymphocytic leukemia (CLL), we used a concomitant combination of chlorambucil and 2-chlorodeoxyadenosine and reported overall (OR) and complete (CR) remission rates of 80% and 20%, respectively. After a median follow-up of 5 years, more than 80% of the responders have had a relapse. In the current phase II study of 27 previously untreated patients with CLL, we used a sequential combination of six cycles of intravenous cyclophosphamide (1 g/m2) plus oral prednisone (100 mg/m2 per day for 5 days) followed by two to six cycles of 2-chlorodeoxyadenosine (5 mg/m2 per day for 5 days). The OR and CR rates were 96% and 33%, respectively. After a median follow-up of 29 months, 35% of the responders have had a relapse. Progression-free survival was significantly better in CR patients than in those with partial remission. However, minimal residual disease was phenotypically detected in four of the nine CR patients. Despite the fact that the current OR and CR rates are superior to those seen in a historical cohort treated with a concomitant schedule, a longer follow-up period is needed to assess the durability of these remissions, and a controlled trial is necessary to estimate the impact on overall survival and toxicity.
authors.affiliation: Mayo Clinic, Rochester, MN 55905, USA.
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
authors.forename: C Y
authors.initials: CY
authors.lastname: Li
authors.forename: C B
authors.initials: CB
authors.lastname: Reeder
authors.forename: S M
authors.initials: SM
authors.lastname: Geyer
authors.forename: C
authors.initials: C
authors.lastname: Allmer
authors.forename: R
authors.initials: R
authors.lastname: Levitt
authors.forename: J C
authors.initials: JC
authors.lastname: Michalak
authors.forename: F
authors.initials: F
authors.lastname: Addo
authors.forename: J E
authors.initials: JE
authors.lastname: Krook
authors.forename: T E
authors.initials: TE
authors.lastname: Witzig
authors.forename: P L
authors.initials: PL
authors.lastname: Schaefer
authors.forename: J A
authors.initials: JA
authors.lastname: Mailliard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017338:Cladribine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D017338:Cladribine; D003520:Cyclophosphamide; D011241:Prednisone